DT-7012 clinical trials
Also written DT-7012.
How each study uses DT-7012 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the DT-7012 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- DT-7012
- 3
Studies by the year they started
2 studies that test it; most in 2025 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Gustave Roussy, Cancer Campus, Grand Paris (1) · Assistance Publique - Hôpitaux de Paris (1) · Domain Therapeutics Australia Pty Ltd (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test DT-7012.
- Sep 2027Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid TumorsPhase 1/2 · Domain Therapeutics Australia Pty Ltd
Studies
Open first, then newest update. How each study uses DT-7012 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Doxorubicin With or Without DT-7012 in Advanced Soft Tissue SarcomaNot yet recruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07802652Written as DT-7012
- Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid TumorsRecruitingPhase 1/2Domain Therapeutics Australia Pty LtdNCT06819735Written as DT-7012
- A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)Not yet recruitingEarly Phase 1Assistance Publique - Hôpitaux de ParisNCT07213882Written as DT-7012